A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

NCT02756728 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Full clinical hold from FDA

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: BI-505
OTHER: High dose melphalan
OTHER: Autologous stem cell transplantation

Sponsor

BioInvent International AB